Evommune (EVMN) Free Cash Flow (2024 - 2026)
Evommune's (EVMN) quarterly Free Cash Flow came in at -$27.5 million in Q1 2026, down 15.24% year-on-year from -$32.5 million in Q1 2025, and down 65.88% on a QoQ basis from -$16.6 million in Q4 2025.
Evommune (EVMN) Free Cash Flow (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Free Cash Flow data on file, last reported at -$27.5 million in Q1 2026.
- On a quarterly basis, Free Cash Flow fell 15.24% year-over-year to -$27.5 million in Q1 2026; TTM through Mar 2026 was -$68.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$76.5 million, down 31.21% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$27.5 million, down from -$16.6 million in the prior quarter.
- Over the last five years, Free Cash Flow for EVMN reached as high as -$16.6 million in Q4 2025 and fell as low as -$27.5 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$21.6 million across 3 years, with a median of -$21.2 million in 2024.
- Across the five-year window, Free Cash Flow grew 10.31% in 2025 and dropped 15.24% in 2026, its largest moves.
- Year by year, Free Cash Flow stood at -$18.5 million in 2024, then increased by 10.31% to -$16.6 million in 2025, then slumped by 65.88% to -$27.5 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$27.5 million in Q1 2026, -$16.6 million in Q4 2025, and -$23.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | -27.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.54 Mn |
| Mar 31, 2026 | -27.54 Mn |
| Dec 31, 2025 | -16.60 Mn |
| Dec 31, 2025 | -16.60 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Dec 31, 2024 | -18.51 Mn |
| Dec 31, 2024 | -18.51 Mn |